Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06546930 · ClinicalTrials.gov registry record · NA

Device Use Reimagined Through Education And Mentorship

A NA study of Diabetes Mellitus, Type 1, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
3
Study locations

NCT06546930: Recruiting NA study of Diabetes Mellitus, Type 1, sponsored by University of California, San Francisco.

NCT06546930 is a NA study of Diabetes Mellitus, Type 1 that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 120 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06546930, a NA study of Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
3
Study locations

Study Summary

Diabetes technology, such as insulin pumps and continuous glucose monitoring devices, can help improve glucose control for people with type 1 diabetes (T1D), which keeps them at lower risk for diabetes complications, but many Latinx adolescents, who make up the largest marginalized ethnic group of youth with T1D in California, use these devices less often and have less optimal glucose control compared to White youth. In phase 1 of this project, we worked directly with Latinx youth, their families, and diabetes care team members in California to develop DREAM, Device use Reimagined through Education And Mentorship, a virtual peer group (VPG) intervention that will encourage and support the use of diabetes devices in Latinx adolescents with T1D. The goals for phase 2 (intervention) of this project are to evaluate the feasibility and acceptability of the stakeholder-informed VPG intervention, and evaluate clinical and person-centered outcomes.

Primary Outcome

Captures personal and family background (e.g. gender, income)

Conditions Studied

Interventions

  • BEHAVIORAL DREAM intervention

Study Locations (3)

California

  • University of California, Davis - Davis
  • Children's Hospital Los Angeles - Los Angeles
  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-10-11
Est. Completion 2026-05-31
Phase NA

What NCT06546930 shows while recruiting

NCT06546930 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which DREAM intervention is the first listed.

NCT06546930 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06546930 about?

NCT06546930 is a clinical study titled "Device Use Reimagined Through Education And Mentorship". Diabetes technology, such as insulin pumps and continuous glucose monitoring devices, can help improve glucose control for people with type 1 diabetes (T1D), which keeps them at lower risk for diabetes complications, but many Latinx adolescents, who make up the largest marginalized ethnic group of y...

What is the current status of trial NCT06546930?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-10-11. Estimated completion is 2026-05-31.

What conditions does trial NCT06546930 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT06546930?

The interventions under investigation include: DREAM intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT06546930?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06546930 being conducted?

This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06546930's enrollment target sits among peer trials

120 45th of 118 higher than 73 of 118 other Diabetes Mellitus, Type 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06546930, the US trial registry maintained by the National Library of Medicine. NCT06546930 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.